PCA3 and posterior cortical atrophy: The ExoDx Prostate (IntelliScore) test, which analyzes the exosomal RNA expression of PCA3 and TMRPSS2-ERG from non-DRE urine, has been reported in two trials to have better sensitivity than the existing risk calculator to predict high-grade PCa (GS ≥ 7) at initial biopsy, and the IntelliScore test could defer unnecessary biopsies [26, 27].